Abstract library

16 results for "australia".
#2117 Neuroendocrine Tumors: An Australian Experience
Introduction: Neuroendocrine tumours (NETs) in Australia are rare, but are rising in incidence.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr Vivek Ashoka Menon
#1731 Neuroendocrine Neoplasm Trends over 32 Years in Queensland, Australia
Introduction: Incidence of Neuroendocrine neoplasms (NENs) has been increasing worldwide.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: A/Prof David K Wyld
Authors: Wyld D K, Wan M H, Moore J
#600 Neuroendocrine Neoplasms: Epidemiological Trends in Queensland, Australia
Introduction: Various studies pertaining to neuroendocrine neoplasms (NENs) have revealed trends in incidence and mortality over time, and regional variations. The WHO 2010 classification has attempted to more accurately reflect the differing prognoses of this heterogeneous patient population by defining various patient subsets.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. Darshit A Thaker
Authors: Hansen A, Zarate D, Wyld D
Keywords: NEC
#1073 The Clinical Oncology Society of Australia (COSA) SIGNETURe Neuroendocrine Tumor (NET) Registry of Australia: First Report of Patient Characteristics and Patterns of Care
Introduction: NETs remain a relatively rare malignancy. Clinical trials are often hindered by the limited number of patients available and thus registries provide important information about patterns of care and patient outcomes.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: A/Prof Timothy Price
Keywords: Registry
#412 Single Institutional Series of Neuroendocrine Tumors Managed in the Australian Capital Territory
Introduction: Neuroendocrine tumors (NETs) have been regarded as indolent tumors with significantly variable clinical behavior. Limited information is available on long-term clinical outcome and clinically applicable prognostic factors.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Laeeq Malik
Authors: Malik L, Chua Y, Yip D, Butt N, ...
#880 Novel Succinate Dehydrogenase Subunit B Intronic Mutation in an Australian Kindred with Variable Clinical and Imaging Phenotype Necessitating Different Treatment Modalities Including 131-I MIBG and 177-Lutetium DOTATATE
Introduction: SDH B mutation has variable functional imaging phenotype challenging in terms of diagnosis, treatment modalities and follow-up.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Kevin Lee
Authors: Lee K, Conway L, Burge M, Wyld D, ...
Keywords: SDHB, Paraganglioma
#1366 CommNETS: Formation of an International Commonwealth Countries NET Partnership
Introduction: Neuroendocrine tumours (NETs) care is challenging in Canada, Australia and New Zealand due to small populations in large geographical space, limited drug funding, and lack of NET awareness. There is a need for collaboration to focus research and improve care and outcomes for NET patients in these nations with similar health systems.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Dr. Simron Singh
Authors: Singh S, Lawrence B, Chan D, Pavlakis N, ...
Keywords: research, society
#151 Rationale for combining mTOR with other targeted agents in the treatment of neuroendocrine tumors
Introduction: Advanced neuroendocrine tumors (NETs) are aggressive and incurable with standard treatment. Many cellular targets are being evaluated in this patient population, including mammalian target of rapamycin (mTOR), a kinase that is the central regulator of several signaling pathways related to cell growth, angiogenesis, and bioenergetics. Because mTOR serves as a neoplastic switch activated by many cancer-related mutations, mTOR inhibition may have broad efficacy across tumor types, including NETs. Somatostatin analogs (SSAs) have long been used to treat carcinoid symptoms in NET patients. The SSA octreotide long-acting release (LAR) demonstrated significant antitumor effects against advanced midgut NETs in the phase III PROMID study.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kjell Öberg
Authors: Öberg K, Yao J C, ...
#1291 How Long Is the Piece of String? – How Patients Negotiate the Uncertainties of a NET Diagnosis
Introduction: NET Patient Interviews
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Dr David Wyld
Authors: Wyld D, Plage S, Burge M, Broom A, ...
Keywords: Interviews
#1358 Identifying and Prioritising Gaps in Neuroendocrine Tumour Research - Results of the Delphi Consensus Project of the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETS)
Introduction: The newly formed CommNETS group used the robust Delphi methodology with broad stakeholder engagement to form a strategic research agenda.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: A/P Eva Segelov